Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjögren’s syndrome

Blood

Volumn 122, Issue 25, 2013, Pages 4068-4076

  Nocturne, Gaetane ^a   Boudaoud, Saida ^a   Miceli Richard, Corinne ^a,b   Viengchareun, Say ^a   Lazure, Thierry ^b   Nititham, Joanne ^c   Taylor, Kimberly E ^c   Ma, Averil ^c   Busato, Florence ^d   Melki, Judith ^e   Lessard, Christopher J ^f   Sivils, Kathy L ^f   Dubost, Jean Jacques ^g   Hachulla, Eric ^h   Gottenberg, Jacques Eric ⁱ   Lombès, Marc ^a   Tost, Jorg ^d   Criswell, Lindsey A ^c   Mariette, Xavier ^a,b  

^a INSERM   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^e Universite Paris Sud   (France)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^g SERVICE DE RHUMATOLOGIE   (France)

^h UNIV LILLE   (France)

ⁱ HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

A20 PROTEIN; ADENINE; AMINO ACID; AZATHIOPRINE; DNA; GUANINE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; MESSENGER RNA; METHOTREXATE; PROTEIN; PROTEIN VARIANT; RITUXIMAB; RO ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; AUTOIMMUNITY; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; ENZYME ACTIVATION; FOLLICULAR LYMPHOMA; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIATION; GERMLINE MUTATION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTIC LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MARGINAL ZONE LYMPHOMA; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPORTER GENE; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; SJOEGREN SYNDROME; SOMATIC MUTATION; SPLENIC MARGINAL ZONE LYMPHOMA; T CELL LYMPHOMA; WHOLE EXOME SEQUENCING; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; EXON; FEMALE; FOLLOW UP; GENETICS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; METABOLISM; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SJOGREN'S SYNDROME;

DNA-BINDING PROTEINS; EXONS; FEMALE; FOLLOW-UP STUDIES; GERM-LINE MUTATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; NEOPLASM PROTEINS; NF-KAPPA B; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SJOGREN'S SYNDROME;

EID: 84892848904     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-503383     Document Type: Article

References (22)

1. Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 2000; 289(5488):2350-2354.
2. Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009;114(12): 2467-2475.
3. Musone SL, Taylor KE, Nititham J, et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun. 2011;12(3):176-182.
4. Ma A, Malynn BA. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol. 2012;12(11):774-785.
5. Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet. 2008;40(9):1062-1064.
6. Bi Y, Zeng N, Chanudet E, et al. A20 inactivation in ocular adnexal MALT lymphoma. Haematologica. 2012;97(6):926-930.
7. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009;459(7247):712-716.
8. Novak U, Rinaldi A, Kwee I, et al. The NF-kappaB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood. 2009;113(20): 4918-4921.
9. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009;206(5):981-989.
10. Du MQ. MALT lymphoma: many roads lead to nuclear factor-κb activation. Histopathology. 2011;58(1):26-38.
11. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165(20):2337-2344.
12. Vitali C, Bombardieri S, Jonsson R, et al; European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-558.
13. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
14. Dieudé P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 2009;60(8):2472-2479.
15. Kosoy R, Nassir R, Tian C, et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat. 2009;30(1):69-78.
16. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther. 2011;13(1):101.
17. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904-909.
18. Adrianto I, Wen F, Templeton A, et al; BIOLUPUS and GENLES Networks. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011;43(3):253-258.
19. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9): 826-833.
20. Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209(9):1553-1565.
21. Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209(9):1537-1551.
22. Snow AL, Xiao W, Stinson JR, et al. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J Exp Med. 2012;209(12): 2247-2261.